In a move that could reshape the landscape of preclinical drug development, the Food and Drug Administration (FDA) recently announced a plan to phase out its requirement for use of animal models in evaluating monoclonal antibodies (mAbs) and other drug candidates.
Retinitis pigmentosa (RP) and retinal dystrophy are debilitating genetic disorders that lead to progressive vision loss due to the degeneration of photoreceptor cells in the retina. Despite advances in genetic research, effective treatments remain limited, making the development of innovative research models crucial. Organoids and Mesh MEA (microelectrode array, also referred to as multielectrode array) technology from Multi Channel Systems have emerged as powerful tools in studying these diseases, providing insights into retinal function and potential therapeutic approaches.
Unlike traditional MEA recordings that can only measure field potentials, the IntraCell uses a laser to precisely optoporate cardiomyocytes underneath each electrode.
According to a recent study published by The Lancet Neurology with contributions from the World Health Organization (WHO), neurological conditions such as, dementia, epilepsy, stroke, and migraine affect more than three billion people worldwide, making these conditions the leading cause of illness and disability globally. Despite advances in neuroscience research, many of these conditions do not have fully effective treatments, making the development of innovative therapies a pressing need.
Microelectrode arrays – also known as “multielectrode arrays” or MEAs – are powerful tools used in neuroscience, cardiac research, and pharmacology to study the electrical activity of excitable tissues like neurons and cardiac cells. But what exactly is an MEA system, and how do they work?
